The awakening time of the original innovative drug

new medical research

Today, an article titled "The Big Bet on Innovative Drugs: A Dream of 200 Billion Dollars in 4 Years" was swiped on the Moments, saying that "many "innovative drugs" in China are not really innovative drugs, but A dividend of times and policies"
.
In the past 10 years, many innovative drug companies have emerged in China, and there have also been some biotech companies that have a certain influence on the world stage, but in general, they are still in the exploratory stage

Drug source analysis

New drug development is a diversity problem, not a scale problem

• Although large pharmaceutical companies have strong financial resources, they are not superior to small biotech companies in discovering new mechanism drugs, which shows that although money is impossible, money is not everything
.
Luck is one of the things money can't buy.

Reference: https://bcf.
princeton.
edu/wp-content/uploads/2021/01/Combined.
pdf

FIC is as difficult and as rare as BIC
.

• Any project involving a new therapeutic hypothesis exposes the reality of our highly ignorant knowledge
.
FIC is the ratio of standard therapy with a different mechanism, BIC is the ratio of therapy with the same mechanism, but it is difficult to win

Reference: https://image-src.
bcg.
com/Images/What_Matters_Most_Biopharma_tcm81-95831.
pdf

The innate qualification of the compound is important, but the acquired culture may be more important

• Keytruda, Lipitor, Humira and other products have a lot to do with the properties of the compounds, but the clinical development and marketing capabilities of the manufacturers behind them are equally important
.
Oranges in Huainan are oranges, and oranges in Huaibei are oranges.

Reference: https:// Track unmet medical needs, not U.

New drugs have a longer cycle and higher risks than other high-tech fields, and the existing VCs in the West are not the best model
.
The domestic VC exit time is shorter, which intensifies the contradiction